美股A股
StockGist

Novo Nordisk A/S

NVONYSE · Healthcare · Drug Manufacturers - GeneralCheap
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, t…
$41.63+2.41%
报价 2026-11-13
市值
$183.52B
EV
–
PE (TTM)
10.3x
预期 PE
–
52 周区间距高点 -34.9%
$35.29$63.98

筛选结果

pipeline · 2026-11-13
Keep✗ 高增长✓ Cheap✗ GARP
Cheap Pool: PE <= 12, EV/EBITDA <= 8

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

同行业市值相近 · Drug Manufacturers - General
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
NVONovo Nordisk A/S$183.52B+2.4%–78.2%10.3x7.2x–Cheap
NVSNovartis AG$303.12B+0.2%–76%20.2x13.5x–
AZNAstraZeneca PLC$286.06B+0.0%–78.2%27.5x15.4x–
AMGNAmgen Inc.$251.89B-0.3%+8.4%70.5%24.4x12.5x26.3x
GILDGilead Sciences, Inc.$208.48B+0.1%+7.2%81.1%20.0x14.5x14.9x
PFEPfizer Inc.$164.67B+0.2%+1.7%72.8%37.3x17.7x14.7x
BMYBristol-Myers Squibb Company PFD CONV 2$129.66B+1.8%+4.6%67.7%16.5x10.5x14.0x
SNYSanofi$116.66B-0.2%–71.7%8.9x9.7x–
GSKGSK plc$101.41B+0.5%–72.5%13.7x7.8x–
同行中位数––+5.9%72.6%20.1x13.0x14.8x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

报告货币 DKK(非美元)
Metric
2026-09-30
Q3 2026
2026-06-30
Q2 2026
2026-03-31
Q1 2026
2025-12-31
Q4 2025
2025-09-30
Q3 2025
2025-06-30
Q2 2025
2025-03-31
Q1 2025
2024-12-31
Q4 2024
RevenueDKK 79.2BDKK 78.49BDKK 96.82BDKK 79.14BDKK 74.98BDKK 76.86BDKK 78.09BDKK 85.68B
Gross Margin77%78.2%86%80.9%76.1%83.3%83.5%84.8%
Operating Margin29.1%34.5%61.6%40.1%31.6%43.5%49.7%42.9%
Net IncomeDKK 16.74BDKK 20.99BDKK 48.56BDKK 26.89BDKK 20.01BDKK 26.5BDKK 29.03BDKK 28.23B
Diluted EPS3.794.7410.916.044.55.966.536.33
Operating Cash FlowDKK 41.24BDKK 55.2BDKK 24.08BDKK 7.62BDKK 46.11BDKK 40.79BDKK 24.59BDKK 12.3B

研究材料